Tesamorelin

Tesamorelin is the rare peptide that doesn't require you to extrapolate from rat studies or rely on anecdotal reports from internet forums. It has current FDA approval, robust Phase III clinical trial data, and a well-characterized mechanism for reducing visceral adipose tissue — the metabolically dangerous fat that accumulates around internal organs. Its brand name is Egrifta, and its approved indication is the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That approved indication is narrow, but the peptide's mechanism has much broader implications that have made it one of the most prescribed growth hormone secretagogues in anti-aging and functional medicine clinics.

This guide covers tesamorelin's pharmacology, clinical trial evidence, the specific visceral fat data that distinguishes it from other secretagogues, side effect profile, vendor landscape analysis across 29 vendors and 156 tested samples, and how it compares to sermorelin, CJC-1295, and direct growth hormone replacement.

What Is Tesamorelin?

Tesamorelin acetate is a synthetic analog of human growth hormone-releasing hormone (GHRH), consisting of all 44 amino acids of endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus. This modification distinguishes it from natural GHRH and provides enhanced stability and resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), the enzyme primarily responsible for GHRH's short half-life in circulation.

Unlike sermorelin, which is a truncated 29-amino-acid fragment of GHRH, tesamorelin is the full-length GHRH sequence with a chemical modification. This full-length structure with enhanced stability gives tesamorelin a longer duration of action than sermorelin, though still substantially shorter than the DAC-modified CJC-1295.

Tesamorelin was developed by Theratechnologies Inc. and received FDA approval in November 2010 under the brand name Egrifta. It was subsequently reformulated as Egrifta SV (a reduced-volume formulation requiring less injection volume) in 2019. Both formulations remain commercially available by prescription.

How Tesamorelin Works

GHRH Receptor Activation

Tesamorelin binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. The mechanism is fundamentally the same as natural GHRH — the hexenoic acid modification improves pharmacokinetics without altering receptor binding or downstream signaling.

Like sermorelin, tesamorelin preserves the hypothalamic-pituitary feedback axis. Growth hormone and IGF-1 released in response to tesamorelin feed back to suppress further GH release through somatostatin and direct pituitary effects. This provides inherent dose-limiting protection against GH excess — a safety advantage over direct GH injection.

Why Visceral Fat Specifically?

The question most people ask about tesamorelin is why it's specifically effective for visceral fat rather than subcutaneous fat or total body weight. The answer involves GH's preferential effects on visceral adipose tissue (VAT).

Visceral adipocytes have a higher density of GH receptors and greater sensitivity to GH-mediated lipolysis compared to subcutaneous adipocytes. When GH levels increase, visceral fat is preferentially mobilized because these cells are more responsive to GH's lipolytic signals. This is not unique to tesamorelin — it's a property of GH biology generally — but tesamorelin's robust GH stimulation makes this effect clinically meaningful and measurable.

Additionally, visceral fat accumulation itself is associated with relative GH deficiency. Visceral adiposity suppresses GH secretion through increased free fatty acid levels and enhanced somatostatin tone. This creates a vicious cycle: more visceral fat leads to less GH, which leads to more visceral fat. Tesamorelin can break this cycle by restoring GH pulsatility despite the suppressive effects of existing visceral adiposity.

IGF-1 Elevation

Tesamorelin consistently increases serum IGF-1 levels, with clinical trial data showing mean increases of approximately 50-100 ng/mL from baseline (roughly 30-50% elevation depending on baseline levels). This IGF-1 elevation is relevant both to tesamorelin's beneficial effects (tissue repair, body composition) and to its theoretical risks (potential cancer promotion — discussed in the safety section).

Clinical Trial Evidence

Tesamorelin's evidence base is among the strongest of any peptide in the secretagogue class, with multiple Phase III randomized controlled trials supporting its FDA approval.

Phase III Trials in HIV Lipodystrophy

The pivotal trials that led to FDA approval enrolled HIV-infected patients with excess abdominal fat (lipodystrophy) — a common side effect of antiretroviral therapy. These trials demonstrated:

Visceral fat reduction: In the combined Phase III data, tesamorelin 2 mg daily reduced visceral adipose tissue (measured by CT scan) by approximately 15-18% from baseline after 26 weeks of treatment. The placebo group showed no significant change. This reduction was statistically significant and clinically meaningful — it represents a substantial decrease in the most metabolically dangerous fat compartment.

Trunk fat reduction: Tesamorelin also reduced total trunk fat, though the effect was more pronounced for visceral than subcutaneous abdominal fat, consistent with GH's preferential visceral lipolytic activity.

Lipid improvements: Some trials showed modest improvements in triglyceride levels and cholesterol ratios, though these effects were not consistent across all studies and were not part of the primary endpoints.

Reversibility: An important finding from the extension studies: when tesamorelin was discontinued, visceral fat reaccumulated to near-baseline levels within 3-6 months. This indicates that tesamorelin's visceral fat reduction requires ongoing treatment and doesn't produce permanent structural changes in adipose tissue distribution.

Cognitive Effects

An intriguing secondary finding from tesamorelin research involves cognitive function. A study in cognitively normal and mildly impaired older adults found that tesamorelin treatment was associated with improved executive function and verbal memory compared to placebo. The mechanism likely involves GH and IGF-1 effects on neuroplasticity, cerebrovascular function, and amyloid-beta clearance.

This cognitive data is preliminary but has generated significant interest, particularly in the context of Alzheimer's disease prevention research. Several ongoing studies are investigating whether sustained tesamorelin treatment can slow cognitive decline in at-risk populations.

NAFLD/NASH Data

Tesamorelin has also shown promising results in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A randomized controlled trial in HIV-infected patients with NAFLD found that tesamorelin significantly reduced liver fat content and prevented NAFLD progression, with some patients achieving complete resolution of hepatic steatosis.

This hepatic fat reduction is mechanistically consistent with GH's role in hepatic lipid metabolism and adds another dimension to tesamorelin's metabolic profile beyond visceral fat reduction.

Dosing and Administration

FDA-Approved Dosing

The FDA-approved dose of tesamorelin is 2 mg administered subcutaneously once daily. This is the dose used in the pivotal Phase III trials and represents the standard starting point for clinical use.

The injection is typically given in the abdomen, rotating injection sites to prevent lipodystrophy. Unlike sermorelin, tesamorelin does not need to be strictly timed to bedtime, though many clinicians still recommend evening administration to complement natural nocturnal GH release.

Anti-Aging/Off-Label Dosing

In anti-aging and functional medicine settings, tesamorelin dosing often varies from the FDA-approved protocol:

• Standard off-label dose: 1-2 mg subcutaneously daily
• Reduced frequency protocols: Some clinicians prescribe 2 mg 5 days per week or every other day
• Lower dose protocols: 0.5-1 mg daily for patients primarily interested in the sleep and recovery benefits rather than maximum visceral fat reduction

The lower dose and reduced frequency protocols lack clinical trial support and are based on clinical experience and patient tolerance rather than controlled data.

Reconstitution and Storage

Tesamorelin (both branded Egrifta and compounded versions) requires reconstitution with sterile water before injection. Once reconstituted, it should be refrigerated and typically used within 14-28 days depending on the preparation. The peptide is sensitive to heat and agitation — reconstituted vials should not be shaken, frozen, or exposed to temperatures above room temperature.

Side Effects and Safety

Common Side Effects

From the Phase III trial data, the most commonly reported adverse events include:

• Injection site reactions: Erythema, pruritus, pain, or swelling at the injection site (reported in approximately 10-15% of patients)
• Arthralgia: Joint pain, typically mild to moderate (8-10%)
• Peripheral edema: Fluid retention, particularly in extremities (5-7%)
• Myalgia: Muscle pain (4-5%)
• Paresthesia: Tingling or numbness, typically in extremities (3-5%)

These side effects are largely consistent with GH elevation effects and are generally dose-dependent and reversible upon dose reduction or discontinuation.

Glucose Metabolism

This is the most clinically significant safety consideration with tesamorelin. GH has well-established anti-insulin effects, and the Phase III trials showed a modest but statistically significant increase in fasting glucose and HbA1c in tesamorelin-treated patients compared to placebo.

The magnitude of glucose elevation was generally small (mean fasting glucose increase of approximately 5-10 mg/dL), but it was clinically meaningful in patients with pre-existing impaired glucose tolerance. Approximately 4% of tesamorelin-treated patients developed new-onset diabetes in clinical trials compared to about 2% of placebo-treated patients.

This glucose effect is the primary reason monitoring is essential during tesamorelin treatment. Fasting glucose and HbA1c should be checked before starting treatment and at regular intervals (typically every 3-6 months) during ongoing use.

IGF-1 and Cancer Risk

Like all GH secretagogues, tesamorelin raises IGF-1 levels, and elevated IGF-1 has been epidemiologically associated with increased risk of certain cancers. The FDA label for Egrifta specifically notes this concern and recommends against use in patients with active malignancies.

Whether the IGF-1 elevations produced by tesamorelin at therapeutic doses carry meaningful cancer risk is unknown. The clinical trials were not designed or powered to detect differences in cancer incidence. However, the theoretical concern is legitimate and should be discussed with patients, particularly those with family history of hormonally-sensitive cancers.

Hypersensitivity

Rare hypersensitivity reactions, including anaphylaxis, have been reported with tesamorelin. Patients should be counseled on the signs of allergic reaction and the first injection should ideally be administered in a clinical setting where observation is possible.

Vendor Landscape and Testing Data

Our testing database includes data from 29 vendors across 156 tested samples of tesamorelin. This is a substantial dataset that reveals important patterns in the compounded tesamorelin market.

Purity Analysis

Across the 156 samples tested:

• Mean purity: 94.2% (acceptable but lower than ideal)
• Range: 78.1% to 99.6%
• Samples meeting greater than 95% purity threshold: 62%
• Samples below 90% purity: 18%

The 18% of samples falling below 90% purity is concerning and represents a meaningful risk for patients sourcing tesamorelin from lower-quality compounding pharmacies. Common impurities include oxidized variants, truncated sequences, and residual solvents from the synthesis process.

Quantity Accuracy

Labeled quantity vs. actual measured quantity showed meaningful divergence in a subset of samples:

• Within 10% of labeled quantity: 71% of samples
• More than 20% deviation from labeled quantity: 14% of samples
• Overcount (more peptide than labeled): 9% of samples
• Undercount (less peptide than labeled): 23% of samples

The tendency toward undercounting means patients may be receiving less tesamorelin than their prescribed dose, potentially explaining variable clinical responses.

For detailed vendor-specific testing results, see our peptide vendor testing database.

Tesamorelin vs. Other Secretagogues

Tesamorelin vs. Sermorelin

Both are GHRH analogs, but tesamorelin has several advantages:

• Full-length GHRH(1-44) structure vs. sermorelin's truncated GHRH(1-29)
• Current FDA approval with active manufacturing vs. sermorelin's discontinued status
• Robust Phase III visceral fat reduction data vs. sermorelin's more limited clinical evidence
• Enhanced stability and longer duration of action

The primary advantage of sermorelin is cost — it's typically less expensive through compounding pharmacies.

Tesamorelin vs. CJC-1295

CJC-1295 with DAC has a much longer half-life (6-8 days vs. tesamorelin's shorter duration), producing more sustained GH elevation. Tesamorelin has the advantage of robust FDA-approved clinical trial data, while CJC-1295's human evidence is more limited. The choice between them often comes down to whether clinicians prioritize clinical evidence (tesamorelin) or dosing convenience and sustained GH elevation (CJC-1295).

Tesamorelin vs. MK-677

MK-677 is an oral, non-peptide GH secretagogue that works through the ghrelin receptor rather than the GHRH receptor. MK-677's advantages are oral administration and 24-hour GH elevation. Its disadvantages relative to tesamorelin include greater appetite stimulation, more pronounced insulin resistance concerns, and less robust clinical trial data for visceral fat reduction specifically.

Who Should Consider Tesamorelin

Based on the clinical evidence, tesamorelin is most rationally considered by:

• HIV patients with lipodystrophy: This is the FDA-approved indication with the strongest evidence
• Adults with excess visceral adipose tissue: Particularly those with metabolically unhealthy fat distribution patterns and documented GH decline
• Patients with NAFLD/NASH: Based on emerging evidence of hepatic fat reduction
• Those prioritizing evidence-based peptide therapy: Tesamorelin's clinical trial data is among the strongest of any secretagogue

Who Should Avoid Tesamorelin

• Patients with active malignancies or disruption of the hypothalamic-pituitary axis by tumors
• Patients with uncontrolled or poorly managed diabetes
• Individuals with known hypersensitivity to tesamorelin or mannitol (an excipient in Egrifta)
• Pregnant individuals (tesamorelin is Pregnancy Category X)
• Patients with pre-existing pituitary surgery or radiation that limits somatotroph reserve

The Bottom Line

Tesamorelin represents what more peptides should aspire to: robust clinical evidence, FDA approval, a well-characterized mechanism, and quantifiable outcomes measured by objective imaging (CT-measured visceral fat). It genuinely reduces visceral adipose tissue by 15-18% over 26 weeks, has an emerging evidence base for cognitive function and liver fat reduction, and has a manageable side effect profile when properly monitored.

The caveats are equally important: the visceral fat reduction reverses when treatment stops, there is a real glucose metabolism concern that requires monitoring, the IGF-1 elevation carries theoretical cancer risk, and compounded versions vary significantly in quality. Tesamorelin is not a permanent solution and not without trade-offs.

For patients who want a growth hormone secretagogue with the strongest evidence base and are willing to commit to ongoing treatment with proper monitoring, tesamorelin is arguably the best-supported option currently available. For broader context on the secretagogue landscape, see our profiles on sermorelin, CJC-1295, ipamorelin, and GHRP-2.